| خلاصه مقاله | Background and Aims
Following a stroke, it is typical to encounter post-stroke cognitive impairment (PSCI), which may lead to challenges
in memory, focus, spatial awareness, and cognitive functions. Lack of conclusive evidence makes it uncertain which
particular pharmacological interventions to suggest. Hence, this study examines the efficacy of pharmacological
interventions in managing PSCI.
Methods
A systematic review of randomized controlled trials was performed using PubMed, Scopus, Web of Science, and
Embase from inception to January 2023, in the English language. RCTs involving different pharmacological
interventions for PSCI with an outcome of cognition measured using the assessment scales of cognitive function
such as MoCA (Montreal Cognitive Assessment) or MMSE (Mini-mental State Examination) were included.
Results
Overall, 2073 cases from 12 studies were included in this systematic review. Most of the RCTs included studied only
patients of ischemic stroke type. The study explored various medications for improving cognitive function in
patients with PSCI and most of which have shown promising results in enhancing cognitive function in PSCI
patients. Among them, rhGH, nimodipine, and donepezil were identified as the most effective treatments based on
assessments using MoCA and MMSE.
Conclusions
The results of this study indicate that pharmacological therapy alone or combined with other therapies appears to
be effective in improving the cognition symptoms of PSCI survivors. In the future, cognition needs to be
recognized and more accurate assessment methods for PSCI
are required for diagnosis and to develop more effective clinical interventions. |